High expression of sushi domain containing 2 (SUSD2) promote cell proliferation in bladder cancer and was associated poor survival outcome.

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Cancer Biology
Translational Research
Presenter Chih Wang
Citation Annals of Oncology (2018) 29 (suppl_9): ix74-ix78. 10.1093/annonc/mdy435
Authors C.J. Wang
  • Division Of Urology, Department Of Surgery, Kaohsiung Veterans General Hospital, 813 - Kaohsiung/TW

Abstract

Background

A number of oncogenes and tumor suppressor genes had been proposed which may play a role in the pathogenesis of bladder cancer. Sushi domain containing 2 (SUSD2) gene has been reported it’s role in tumorigenesis in breast cancer and ovarian cancer. However, there was no data of the gene about bladder cancer yet.

Methods

We searched and collected the patients of bladder cancer from the TCGA database. Total 379 patients of bladder cancer from stage I to IV were investigated for the relationship between SUSD2 genes and cancerous risk or outcome. We also conducted cell biology experiment in vitro for gene knockdown by introducing small interfering RNA to the bladder cancer cell then to monitor the performance of cell cycle at our hospital.

Results

The expression levels of SUSD2 were significantly increased in bladder cancer, and higher expression level was observed in late pathologic stage rather than early stage. Multivariate analysis revealed that high SUSD2 expression levels were significantly correlated with poor overall survival (OS; adjusted hazard ratio [aHR] 1.53, 95% confidence interval [CI] 1.53–2.31, p = 0.043) for bladder cancer. Cell biology experiment also revealed the slower proliferation rate and less ability for colony formation after SUSD2 gene knockdown by introducing small interfering RNA to the bladder cancer cell.

Conclusions

High expression of SUSD2 gene in bladder cancer patients was associated with poor survival outcome and poor pathologic stage.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Chih Jen Wang.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.